Cyclacel Pharmaceuticals Announces Orphan Drug Designation by the FDA for Sapacitabine both in AML and MDS Berkeley Heights, New Jersey – Pharmaceuticals Cyclacel, Inc., a biopharmaceutical company developing oral therapies that target different stages of cell cycle control in the treatment of cancer and other disorders serious, today announced that the U.S.
Seborrheic Dermatitis Treatment and Dandruff Treatment